Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

Better cancer treatment inspired by the foam on your latte

Date: Thursday, February 2, 2023

Culinary arts techniques create new therapeutic materials 

Inspired by the foam on top of lattes, as well as gummy bears and Pop Rocks candies, researchers at the University of Iowa are creating new, biocompatible materials that may improve the effectiveness of chemotherapy and radiation for treating cancers.  

The new materials are known as gas-entrapping materials, or GeMs, which can be formulated as foams, solids, or hydrogels, and are designed to carry high concentrations of a variety of therapeutic gases directly into tissues, including tumors. 

In a new study, published Feb. 2 in the journal Advanced Science, researchers led by James Byrne, MD, PhD, and Jianling Bi, PhD, at the UI, used GeMs to deliver high levels of oxygen directly into tumors. The study showed that this improved the effectiveness of standard chemotherapy and radiation treatments in mouse models of prostate cancer and a type of sarcoma.

Dr. James Byrne holds the modified whipping siphon in his lab at the University of Iowa. Around him are large tanks of pressurized gas.
Dr. Byrne, pictured in his lab, holds a whipping siphon that was reverse-engineered to accept any gas.

“We’ve known for a long time that if you increase the amount of oxygen within a tumor you can make it more responsive to radiation, certain chemotherapies, and even potentially immunotherapies,” says Byrne, UI assistant professor of radiation oncology and a member of Holden Comprehensive Cancer Center at the UI. “However, the challenge has been how to deliver an effective dose of oxygen in a safe, controlled fashion.”

The new study shows that GeMs can significantly increase oxygen levels within solid tumors and render the cancer cells more vulnerable to radiation or chemotherapy. The increased oxygen levels also appeared to improve immune reactivity, which is key to generating a response to immunotherapy.

“These GeMs are very simple, with just three ingredients: the gas, the foaming agents, and the thickening agent,” says Byrne, who also is a UI assistant professor of biomedical engineering. “We use several unique, custom-built pressurized systems to incorporate high concentrations of gas into small volumes of these biocompatible materials, which can be injected or implanted into tissues and allow for prolonged, controlled release of the gas.”

The foam GeMs, for example, are created using a whipping siphon—essentially the same device baristas use to make foams on hot chocolate and frozen coffee drinks—but reverse-engineered to accept various gases, including oxygen. The lab’s whipping siphons use safe, low-cost components found in many processed foods to make the GeMs. By varying the quantity of each component, the researchers can control the release of oxygen from the material. Because the GeMs are manufactured with safe and edible components, Byrne notes that the translatability of these materials for cancer care is likely to be extremely high.

Another advantage is the ability to implant or inject GeMs directly into the tumor. Intratumoral delivery of cancer therapies is an approach that has blossomed over the past decade due to the ability to achieve high concentrations of drugs inside the tumor with low side effects. The foams, in particular, can be injected into areas of the tumor that are harder to treat or remove by surgery.

A close-up image of the whipping siphon dispensing the gas-entrapping foam onto a petri dish. The foam looks similar to whipped cream.
Dr. Byrne demonstrates the use of a whipping siphon to dispense gas-entrapping foam.

“One of the aspects of this project that really excited me was the combination of cancer biology principles with material science to create something that can be really impactful,” says study first author Bi, a research scientist in Byrne’s lab. 

In addition to Byrne, Bi and their colleagues at the UI, the study was a multi-institutional effort involving researchers at Massachusetts Institute of Technology, Beth Israel Deaconess Medical Center, and Harvard Medical School.